A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Phase Ii ◽

Multicenter Study ◽

Growth Factor Receptor ◽

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Annals of Oncology ◽

10.1093/annonc/mdj084 ◽

2006 ◽

Vol 17 (3) ◽

pp. 450-456 ◽

Cited By ~ 171

Author(s):

G. Folprecht ◽

M.P. Lutz ◽

P. Schöffski ◽

T. Seufferlein ◽

A. Nolting ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70181-7 ◽

2006 ◽

Vol 2006 ◽

pp. 258-260

Author(s):

N.H. Hanna

Keyword(s):

Squamous Cell Carcinoma ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Multicenter Study ◽

Growth Factor Receptor ◽

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1354 ◽

2008 ◽

Vol 14 (5) ◽

pp. 1296-1302 ◽

Cited By ~ 63

Author(s):

Ruthann M. Giusti ◽

Kaushikkumar Shastri ◽

Anne M. Pilaro ◽

Chana Fuchs ◽

Ruth Cordoba-Rodriguez ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Drug Administration ◽

Food And Drug Administration ◽

Growth Factor Receptor ◽

Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

Annals of Oncology ◽

10.1093/annonc/mdx393.044 ◽

2017 ◽

Vol 28 ◽

pp. v175 ◽

Cited By ~ 1

Author(s):

T. Buchler ◽

R. Chloupkova ◽

A. Poprach ◽

O. Fiala ◽

I. Kiss ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Growth Factor Receptor ◽

Sequential Therapy ◽

Faculty Opinions recommendation of A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717952895.793458390 ◽

2012 ◽

Author(s):

Maciej S Lesniak

Keyword(s):

Growth Factor ◽

Glioblastoma Multiforme ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Immunohistochemical expression of the epidermal growth factor receptor (EGFR) in colorectal carcinoma: relation with clinicopathological parameters

Journal of Coloproctology (Rio de Janeiro) ◽

10.1590/s2237-93632011000300001 ◽

2011 ◽

Vol 31 (3) ◽

pp. 225-232

Author(s):

Maurício Andrade Azevedo ◽

Bianca Doimo Souza ◽

Ana Maria Amaral Antonio Mader ◽

Lourdes Conceição Martins ◽

Jaques Waisberg

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Growth Factor Receptor ◽

Clinicopathological Parameters ◽

Immunohistochemical Expression ◽

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Frontiers in Oncology ◽

10.3389/fonc.2019.00132 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 10

Author(s):

Karen L. Reckamp ◽

Paul H. Frankel ◽

Nora Ruel ◽

Philip C. Mack ◽

Barbara J. Gitlitz ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Tyrosine Kinase Inhibitor Therapy ◽

Epidermal Growth ◽

Egfr Mutant

ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases

Journal of Thoracic Disease ◽

10.21037/jtd.2017.09.79 ◽

2017 ◽

Vol 9 (10) ◽

pp. 3919-3926 ◽

Cited By ~ 3

Author(s):

Zhengbo Song ◽

Yuhui Zheng ◽

Xuzhou Wang ◽

Haiyan Su ◽

Yiping Zhang ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Lung Adenocarcinoma ◽

Multicenter Study ◽

Growth Factor Receptor ◽

Wild Type ◽

Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity&#

Reviews on Recent Clinical Trials ◽

10.2174/157488706776876463 ◽

2006 ◽

Vol 1 (2) ◽

pp. 113-118 ◽

Cited By ~ 2

Author(s):

Enric Carcereny ◽

Joan Maurel

Keyword(s):

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Clinical Efficacy ◽

Growth Factor Receptor ◽

Advanced Colorectal Carcinoma ◽

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/0360-3016(92)91009-c ◽

1992 ◽

Vol 22 (1) ◽

pp. 225-230 ◽

Cited By ~ 96

Author(s):

Luther W. Brady ◽

Curtis Miyamoto ◽

David V. Woo ◽

Michael Rackover ◽

Jacqueline Emrich ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Malignant Astrocytomas ◽

Epidermal Growth ◽

Iodine 125